Monthly
US$200
Billed every month
Eperisone Hydrochloride Tablets(盐酸乙哌立松片)
Companies, stages and changes, with each record available on this page.
Last 90 days: No longer listed under review: 3 applicationsSupplement delivery: 1 applicationNotification delivery: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders11View records ↓
Under-review filings7View records ↓
This year’s generic filers6View records ↓
NHSA approval numbers13View records ↓
API companies with A status11View records ↓
Chemical-drug catalogue
Loaded records: 11 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 10 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 湖南九典制药股份有限公司 | 湖南九典制药股份有限公司 | 国药准字H20266167 | 2026/09/29 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东京卫制药有限公司 | 山东京卫制药有限公司 | 国药准字H20265310 | 2026/07/21 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 大桐制药（中国）有限责任公司 | 大桐制药（中国）有限责任公司 | 国药准字H20264821 | 2026/06/17 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海安必生制药技术有限公司 | 寿光富康制药有限公司 | 国药准字H20264075 | 2026/04/21 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏吴中医药集团有限公司苏州制药厂 | 江苏吴中医药集团有限公司苏州制药厂 | 国药准字H20256382 | 2025/12/22 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏谦仁生物科技有限公司 | 江苏谦仁生物科技有限公司 | 国药准字H20256268 | 2025/12/16 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南尚众合生物医药有限公司 | 大桐制药（中国）有限责任公司 | 国药准字H20256045 | 2025/11/25 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都硕德药业有限公司 | 成都硕德药业有限公司 | 国药准字H20255554 | 2025/09/23 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| — | 卫材(中国)药业有限公司 | 国药准字H20133175 | 2013/10/10 | 50mg（薄膜衣） | Other drug (其他药品) | CDE |
| 上海博悦生物科技有限公司 | 华益泰康药业股份有限公司 | 国药准字H20266119 | 2026/09/29 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 康普药业股份有限公司 | 康普药业股份有限公司 | 国药准字H20266278 | 2026/10/13 | 50mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 13 distinct approval numbers and 12 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 江苏吴中医药集团有限公司苏州制药厂 | 国药准字H20256382 | 50mg | Category B (乙) | XM03BXY112A001010101504 | NHSA |
| 卫材(中国)药业有限公司 | 国药准字H20133175 | 50mg(薄膜衣) | Category B (乙) | XM03BXY112A001010101693 | NHSA |
| 国药集团宜宾制药有限责任公司 | 国药准字H20040106 | 50mg | Category B (乙) | XM03BXY112A001010102294 | NHSA |
| 青岛国海生物制药有限公司 | 国药准字H20010657 | 50mg | Category B (乙) | XM03BXY112A001010104028 | NHSA |
| 湖南亚大制药有限公司 | 国药准字H20020170 | 50mg | Category B (乙) | XM03BXY112A001010104994 | NHSA |
| 大桐制药(中国)有限责任公司 | 国药准字H20264821 | 50mg | Category B (乙) | XM03BXY112A001010180685 | NHSA |
| 上海安必生制药技术有限公司 | 国药准字H20264075 | 50mg | Category B (乙) | XM03BXY112A001010182990 | NHSA |
| 成都硕德药业有限公司 | 国药准字H20255554 | 50mg | Category B (乙) | XM03BXY112A001010183830 | NHSA |
| 湖南尚众合生物医药有限公司 | 国药准字H20256045 | 50mg | Category B (乙) | XM03BXY112A001010184674 | NHSA |
| 江苏谦仁生物科技有限公司 | 国药准字H20256268 | 50mg | Category B (乙) | XM03BXY112A001010185483 | NHSA |
| 国药集团宜宾制药有限责任公司 | 国药准字H20040106 | 50mg | Category B (乙) | XM03BXY112A001010202294 | NHSA |
| 青岛国海生物制药有限公司 | 国药准字H20010657 | 50mg | Category B (乙) | XM03BXY112A001010204028 | NHSA |
| 湖南亚大制药有限公司 | 国药准字H20020170 | 50mg | Category B (乙) | XM03BXY112A001010204994 | NHSA |
| 大桐制药(中国)有限责任公司 | 国药准字H20264821 | 50mg | Category B (乙) | XM03BXY112A001010280685 | NHSA |
| 成都硕德药业有限公司 | 国药准字H20255554 | 50mg | Category B (乙) | XM03BXY112A001010283830 | NHSA |
| 湖南尚众合生物医药有限公司 | 国药准字H20256045 | 50mg | Category B (乙) | XM03BXY112A001010284674 | NHSA |
| 江苏谦仁生物科技有限公司 | 国药准字H20256268 | 50mg | Category B (乙) | XM03BXY112A001010285483 | NHSA |
| 国药集团宜宾制药有限责任公司 | 国药准字H20040106 | 50mg | Category B (乙) | XM03BXY112A001010302294 | NHSA |
| 青岛国海生物制药有限公司 | 国药准字H20010657 | 50mg | Category B (乙) | XM03BXY112A001010304028 | NHSA |
| 湖南亚大制药有限公司 | 国药准字H20020170 | 50mg | Category B (乙) | XM03BXY112A001010304994 | NHSA |
| 成都硕德药业有限公司 | 国药准字H20255554 | 50mg | Category B (乙) | XM03BXY112A001010383830 | NHSA |
| 湖南尚众合生物医药有限公司 | 国药准字H20256045 | 50mg | Category B (乙) | XM03BXY112A001010384674 | NHSA |
| 江苏谦仁生物科技有限公司 | 国药准字H20256268 | 50mg | Category B (乙) | XM03BXY112A001010385483 | NHSA |
| 青岛国海生物制药有限公司 | 国药准字H20010657 | 50mg | Category B (乙) | XM03BXY112A001010404028 | NHSA |
| 江苏谦仁生物科技有限公司 | 国药准字H20256268 | 50mg | Category B (乙) | XM03BXY112A001010485483 | NHSA |
| 青岛国海生物制药有限公司 | 国药准字H20010657 | 50mg | Category B (乙) | XM03BXY112A001010504028 | NHSA |
| 江苏谦仁生物科技有限公司 | 国药准字H20256268 | 50mg | Category B (乙) | XM03BXY112A001010585483 | NHSA |
| 卫材(中国)药业有限公司 | 国药准字H20041061 | 50mg | Category B (乙) | XM03BXY112A001020101693 | NHSA |
| 青岛国海生物制药有限公司 | 国药准字H20010657 | 50mg | Category B (乙) | XM03BXY112A001020104028 | NHSA |
| 湖南九典制药股份有限公司 | 国药准字H20266167 | 50mg | Category B (乙) | XM03BXY112A001010104942 | NHSA |
| 康普药业股份有限公司 | 国药准字H20266278 | 50mg | Category B (乙) | XM03BXY112A001010105032 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 7 filings and 7 distinct first applicants.
Generic 7
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 苏州弘森药业股份有限公司 | CYHS2600240 | Generic | 2026/01/21 | Not stated by source | CDE |
| 黑龙江亿达鸿药业有限公司 | CYHS2600699 | Generic | 2026/03/23 | Not stated by source | CDE |
| 云鹏医药集团有限公司 | CYHS2600666 | Generic | 2026/03/16 | Not stated by source | CDE |
| 长春澜江医药科技有限公司;植恩生物技术股份有限公司 | CYHS2600582 | Generic | 2026/02/28 | Not stated by source | CDE |
| 安士制药（中山）有限公司 | CYHS2600313 | Generic | 2026/01/30 | Not stated by source | CDE |
| 山西同达药业有限公司 | CYHS2504270 | Generic | 2025/12/12 | Not stated by source | CDE |
| 湖南华纳大药厂股份有限公司 | CYHS2503092 | Generic | 2025/08/23 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 6 filings and 6 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 苏州弘森药业股份有限公司 | CYHS2600240 | Generic | 2026/01/21 | Not stated by source | CDE |
| 黑龙江亿达鸿药业有限公司 | CYHS2600699 | Generic | 2026/03/23 | Not stated by source | CDE |
| 云鹏医药集团有限公司 | CYHS2600666 | Generic | 2026/03/16 | Not stated by source | CDE |
| 长春澜江医药科技有限公司;植恩生物技术股份有限公司 | CYHS2600582 | Generic | 2026/02/28 | Not stated by source | CDE |
| 北京紫萌医药科技有限公司;白云山东泰商丘药业有限公司 | CYHS2600494 | Generic | 2026/02/15 | Not stated by source | CDE |
| 安士制药（中山）有限公司 | CYHS2600313 | Generic | 2026/01/30 | Not stated by source | CDE |
API registrations
Non-component matches: 11 companies with A status and 8 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 盐酸乙哌立松 | 山东新时代药业有限公司 | Y20260000569 | I | Exact ingredient | 2026/07/10 | CDE |
| 盐酸乙哌立松 | 湖南方盛制药股份有限公司 | Y20260000095 | I | Exact ingredient | 2026/02/26 | CDE |
| 盐酸乙哌立松 | 苏州弘森药业股份有限公司 | Y20250000745 | I | Exact ingredient | 2025/07/23 | CDE |
| 盐酸乙哌立松 | 湖南华纳大药厂手性药物有限公司 | Y20250000650 | I | Exact ingredient | 2025/07/22 | CDE |
| 盐酸乙哌立松 | 浙江赛默制药有限公司 | Y20250000669 | I | Exact ingredient | 2025/07/17 | CDE |
| 盐酸乙哌立松 | 河南东泰制药有限公司 | Y20250000369 | I | Exact ingredient | 2025/07/01 | CDE |
| 盐酸乙哌立松 | 植恩生物技术股份有限公司 | Y20250000383 | I | Exact ingredient | 2025/05/08 | CDE |
| 盐酸乙哌立松 | 山东辰龙药业有限公司 | Y20250000304 | A | Exact ingredient | 2026/08/13 | CDE |
| 盐酸乙哌立松 | 湖南九典宏阳制药有限公司 | Y20240001410 | A | Exact ingredient | 2026/07/01 | CDE |
| 盐酸乙哌立松 | 白云山东泰商丘药业有限公司 | Y20240001331 | I | Exact ingredient | 2024/12/02 | CDE |
| 盐酸乙哌立松 | 康普药业股份有限公司 | Y20240000670 | A | Exact ingredient | 2026/01/08 | CDE |
| 盐酸乙哌立松 | 福建南方制药股份有限公司 | Y20240000364 | A | Exact ingredient | 2025/12/17 | CDE |
| 盐酸乙哌立松 | 安徽鼎旺医药有限公司 | Y20240000605 | A | Exact ingredient | 2025/11/10 | CDE |
| 盐酸乙哌立松 | 四川青木制药有限公司 | Y20240000349 | A | Exact ingredient | 2025/07/25 | CDE |
| 盐酸乙哌立松 | 江苏吴中医药集团有限公司苏州制药厂 | Y20230000997 | A | Exact ingredient | 2025/06/21 | CDE |
| 盐酸乙哌立松 | 国药集团宜宾制药有限责任公司 | Y20190002612 | A | Exact ingredient | 2024/04/26 | CDE |
| 盐酸乙哌立松 | 青岛国海生物制药有限公司 | Y20190002225 | A | Exact ingredient | 2024/11/19 | CDE |
| 盐酸乙哌立松 | 湖南亚大制药有限公司 | Y20190001861 | A | Exact ingredient | 2025/02/15 | CDE |
| 盐酸乙哌立松 | Eisai Co., Ltd. | Y20170001587 | A | Exact ingredient | 2025/02/18 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/04No longer listed under review
青岛国海生物制药有限公司
CYHB2650102
Fact date: 2026/11/04 · Site observation date: 2026/11/04
Accepted: 2026/04/28
not on the CDE under-review list in this snapshot; NMPA published approval-document delivery for this acceptance number on 2026/11/03 (approval no.: —; approval date: 2026/11/02); this is a supplemental application, not counted as a new marketing approval · NMPA source · row 7
NMPA · Table row 7 ↗ View source ↗ -
2026/11/02Supplement delivery
青岛国海生物制药有限公司
CYHB2650102
Fact date: 2026/11/02 · Publication date: 2026/11/03 · Site observation date: 2026/11/03
Supplemental application; excluded from new marketing approvals.
View source · Table row 7 ↗ -
2026/10/30No longer listed under review
西洲医药科技（浙江）有限公司;浙江北生药业汉生制药有限公司
CYHS2501939
Fact date: 2026/10/30 · Site observation date: 2026/10/30
Accepted: 2025/05/30
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/10/28Notification delivery
北京紫萌医药科技有限公司
CYHS2600494
Fact date: 2026/10/28 (Publication date) · Publication date: 2026/10/28 · Site observation date: 2026/11/03
Notification delivered; the specific outcome remains to be checked.
View source · Table row 20 ↗ -
2026/10/24No longer listed under review
湖南千金协力药业有限公司
CYHS2502029
Fact date: 2026/10/24 · Site observation date: 2026/10/24
Accepted: 2025/06/09
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Eperisone Hydrochloride Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy